
FDA Actions in Oncology: April 2025 Approvals and Designations
April 2025 saw significant activity in FDA oncology news, with several notable approvals. The FDA approved the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) as a first-line treatment for adult and pediatric patients (≥12 years) with …